Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press2910.17650/1726-9784-2015-14-3-19-28REVIEWSОБЗОРЫ ЛИТЕРАТУРЫCURRENT UNDERSTANDING OF ANTITUMOR IMMUNITYСОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ПРОТИВООПУХОЛЕВОМ ИММУНИТЕТЕShubinaI. Zh.ШубинаИрина Жановна
Russian Federation
irinashubina@mail.ruSergeevA. V.СергеевА. В.
Russian Federation
MamedovaL. T.МамедоваЛ. Т.
Russian Federation
SokolovN. Yu.СоколовН. Ю.
Russian Federation
KiselevskyM. V.КиселевскийМ. В.
Russian Federation
FSBI «N.N. Blokhin RCRC»ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава РоссииCentral Clinical HospitalФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента РФ30092015143192810042018https://bioterapevt.abvpress.ru/jour/article/view/29

The review presents analysis of the papers that discuss mechanisms of antitumor immunity. The role of innate and adaptive immune reactions as well as local and systemic is considered in terms of immune defense in clinical and experimental studies. The article discusses characteristics and role tumor-associated antigens for clinical practice. Various types of immune effector cells, including T-cells, NK-cell, DC, tumor associated macrophages, etc., and cytokines, are discussed regarding their contribution into antitumor immune response. The authors also refer to the hypothesis of “immunoediting” and its part in antitumor immunity.

Проанализированы исследования последних лет, посвященные изучению механизмов противоопухолевого иммунитета. Рассмотрена роль врожденного и приобретенного, а также местного и системного иммунитета в формировании противоопухолевой защиты организма с привлечением клинических и экспериментальных исследований; свойства и значение опухолеассоциированных антигенов для практической онкологии. Показана роль различных иммунокомпетентных клеток, в том числе - Т-клеток, NK-клеток, ДК, опухолеассоциированных макрофагов, а также цитокинов в противоопухолевой иммунной защите организма. Изложена гипотеза «иммуноредактирования» и его роли в формировании механизмов противоопухолевого иммунитета.

противоопухолевый иммунитетиммунокомпетентные клеткииммуноредактированиеantitumor immunityimmune effector cellsimmunoeditingБарышников, А.Ю. Взаимоотношение опухоли и иммунной системы организма // Практическая онкология. - 2003. - Т.4, №3. - С.127-30.Кадагидзе З.Г. NKT-клетки и противоопухолевый эффект // Российский биотерапевтический журнал. - 2011. - Т.10, №3. - С. 9-15.Шубина И.Ж., Чикилева И.О., Михайлова И.Н. и др. Активированные натуральные киллеры в клеточной иммунотерапии // Российский иммунологический журнал. - 2012. - Т. 6(15), № 1. - С. 71-9.Alshaker H.A., Matalka K.Z. IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors // Cancer Cell Int. - 2011. - 23(11). - P. 33-44.Asselin-Paturel C., Trinchieri G. Production of type I interferons: plasmacytoid dendritic cells and beyond // J Exp Med. - 2005. - 202. - Р. 461-5.Booy S., Hofland L., van Eijck C. Potentials of interferon therapy in the treatment of pancreatic cancer // J Interferon Cytokine Res. - 2015. - 35(5). - Р. 327-339.Boyton R.J., Altmann D.M. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease // Clinical and Experimental Immunology. - 2007. - 149. - P. 1-8.Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications // Br Med J. - 1957. - №1(5023). - Р.841-7.Camus M., Tosolini M., Mlecnik B. et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence //Cancer Res. - 2009. - 69. - Р. 2685-93.Cheever M., Allison J.P., Ferris A.S. et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research //Clin Cancer Res. - 2009. - 15. - Р. 5323-37.Coronella J.A., Spier C., Welch M. et al. Antigen driven oligoclonal expansion of tumor-infiltrating В cells in infiltrating ductal carcinoma of the breast //J Immunol. - 2002. - 169. - Р. 1829-36.Diebold S.S. Determination of T-cell fate by dendritic cells // Immunol Cell Biol. - 2008. - 86. - Р. 389-97.Dighe A.S., Richards E., Old L.J., Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors //Immunity. - 1994. - №1. - Р. 447-56.Dunn G.P., Bruce A.T., Ikeda H. et al. Cancer immunoediting: from immunosurveillance to tumor escape //Nat Immunol. - 2002. - №3. - Р. 991-8.Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting // Nat Rev Immunol. - 2006. - 6. - Р. 836-48.Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung //Ned Tijdschr Geneeskd. - 1909. - №5. - Р. 273-90.Ferris R.L., Whiteside T.L., Ferrone S. Immune escape associated with functional defects in antigen processing machinery in head and neck cancer //Clin Cancer Res. - 2006. - № 12. - Р. 3890-5.Ferrone S., Whiteside T.L. Tumor microenvironment and immune escape //Surg Oncol Clin North Am. - 2007. - № 16. - Р. 755-74.Finn O.J., Binder R.J., Brickner A.G. et al. Human tumor antigens as targets of immunosurveillance and candidates for cancer vaccines. In: Gires O. Seliger В., editors. Tumor-associated antigens: identification, characterization, and clinical applications. Weinheim (Germany): Wiley-VCH, 2009. - Р. 23-43.Gresser I., Maury C., Vignaux F. et al. Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice // J Exp Med. - 1988. - 168. -Р. 1271-91.Gumperz J.E. CD1d-restricted “NKT” cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses? // Journal of Leukocyte Biology. - 2004. - 76. - P. 307-14.Hailemichael Y., Overwijk W.W. Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination // Int J Biochem Cell Biol. - 2014. - 53. - Р. 46-50.Jager E., Karbach J., Gnjatic S. et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NYESO- 1-specific immune responses in cancer patients // Proc Natl Acad Sci USA. - 2006. - 103. - Р. 14453-8.Jewett A., Tseng H.C. Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells // J Cancer. - 2011. - №2. - Р. 443-57.June C.H. Adoptive T cell therapy for cancer in the clinic // J Clin Invest. - 2007. - 117. - Р. 1466-76.Kim R., Emi M., Tanabe K. Cancer immunoediting from immune surveillance to immune escape // Immunology. - 2007. - 1. - P. 1-14.Klein G. Tumor antigens //annu rev microbiol. - 1966. - 20. - Р. 223-52.Kryczek I., Banerjee M., Cheng P. et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor microenvironment // Blood. - 2009. - 114. - Р. 1141-9.Lanier L.L. Natural killer cell receptor signaling // Curr Opin Immunol. - 2003. - 15. - Р. 308-14.Luszynski W., Krawczuk-Rybak M., Stasiak-Barmuta A. Myeloid-derived suppressor cells - the new mechanism of immunosuppression in cancer // Postepy Hig Med Dosw. - 2008. - 21(62). - Р. 18-22.Mandapathil M., Szczepanski M.J., Szajnik M. et al. Increased ectonucleotidase expression and activity in Treg of patients with head and neck cancer //Clin Cancer Res. - 2009. - 15. - Р. 6348-57.Manjili M.H. Revisiting cancer immunoediting by understanding cancer immune complexity // J Pathol. - 2011. - 224(1). - P. 5-9.Martinez O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization // Front Biosci. - 2008. - 13. - Р. 453-61.Obeid M., Panaretakis T., Tesniere A. et al. Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from ‘‘Silent’’ to Immunogenic // Cancer Res. - 2007. - 67(17). - P. 7941-5.Oble D.A., Loewe R., Yu P., Mihm M.C. Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma // Cancer Immun. - 2009. - 9. - Р. 3-23.Ochoa A.C., Zea A.H., Hernandez C., Rodri'guez P.C. Arginase, prostaglandins, and myeloid supressor cells in renal cell carcinoma // Clin Cancer Res. - 2007. - 13. - Р. 721-6s.Onji M., Akbar Sk.Md. On dendritic cell-based therapy for cancers // J Zhejiang Univ SCI. - 2005. - 6B(1). - P. 1-3.Parmiani G., De Filippo A., Novellino L., Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials // J Immunol. - 2007. - 178. - Р. 1975-9.Pellegrini M., Mak T. W., Ohashi P.S. Fighting cancers from within: augmenting tumor immunity with cyto kine therapy // Trends Pharmacol Sci. - 2010. - 31(8). - P. 356-63.Provinciali M. Immunosenescence and cancer vaccines // Cancer Immunol Immunother. - 2009. - 58. - Р. 1959-67.Reichert T.E., Strauss L., Wagner E.M. et al. Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma // Clin Cancer Res. - 2002. - № 8. -Р. 3137-45.Romero P., Cerottini J.C., Speiser D.E. The human T cell response to melanoma antigens // Adv Immunol. - 2006. - 92. - Р. 187-224.Schmieder A., Michel J., Schцnhaar K. et al. Differentiation and gene expression profile of tumor-associated macrophages // Semin Cancer Biol. - 2012. - 22(4). - P. 289-97.Seliger B., Quandt D. The expression, function, and clinical relevance of B7 family members in cancer // Cancer Immunol Immunother. - 2012. - 61(8). - Р. 1327-41.Sethi G., Shanmugam M.K., Ramachandran L. et al. Multifaceted link between cancer and inflammation // Biosci Rep. - 2012. - 32(1). - P. 1-15.Shurin G.V., Shurin M.R., Bykovskaja S. et al. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function // Cancer Res. - 2001. - 61. - Р. 363-9.Slavin S.A., Ackerstein R. Or, Shapira M.Y. et al. Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study // Cancer Immunol Immunother. - 2010. - 59. - P. 1511-9.Smyth M.J., Dunn G.P., Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity // Adv Immunol. - 2006. - 90. -Р. 1-50.Smyth M.J., Thia K. Y., Street S.E. et al. Differential tumor surveillance by natural killer (NK) and NKT cells // J Exp Med. - 2000. - 191. - Р. 661-8.Storkus W.J., Falo Jr L.D. A ‘good death’ for tumor immunology // Nature Medicine. - 2007. - 13(1). - P. 28-31.Strauss L., Bergmann C., Szczepanski M. et al. A unique subset of CD4/CD25high/FOXP3 T cells secreting IL-10 and TGFb1 mediates suppression in the tumor microenvironment // Clin Cancer Res. - 2007. - 13. -Р. 4345-54.Tan G.X., Zhang H., Feng H. et al. The Therapeutic Effect of Cytokine-Induced Killer Cells on Pancreatic Cancer Enhanced by Dendritic Cells Pulsed with K-RasMutant Peptide // Clinical and Developmental Immunology. - 2011. - 1. - P. 1-9.Thakur A., Littrup P., Paul E.N. et al. Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study // J Immunother. - 2011. - 34(5). - P. 457-467.Turcotte S., Rosenberg S.A. Immunotherapy for metastatic solid cancers // Adv Surg. - 2011. - 45. - P. 341-60.Vendramini-Costa D.B., Carvalho J.E. Molecular link mechanisms between inflammation and cancer // Curr Pharm Des. - 2012. - 18(26). - Р. 3831-52.Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic interventions // Semin Cancer Biol. - 2006. - 16. - Р. 3-15.Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth // Oncogene. - 2008. - 27. - Р. 5904-12.Yang S., Gattinoni L., Liu F. et al. In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells // Cancer Immunol Immunother. - 2011. - 60(5). - P. 739-49.